Health Minister inaugurates Second AIIMS Oncology Conclave at NCI-AIIMS, Jhajjar

JB Pharma reports revenue growth of 14% in Q3 FY25; Net profit up by 22%

Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24

Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines

The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25

JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr

JB’s domestic business continued to out-perform the market with all our major brands posting strong growth

JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr

Expect the international business including CDMO business to pick-up in the second half of the financial year

Industry’s reaction to Union Budget 2024-25

Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry

JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr

Reports revenue growth of 9% to INR 882 crores in Q2 FY24

JB Pharma publishes sustainability report for FY 2022-23

JB Pharma reported 19% decrease in GHG intensity as compared to last year and commenced its journey of Scope 3 emissions

JB Pharma completes 1 year of its identity launch

Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23

JB Pharma records revenue growth of 22% to Rs. 762 Cr

Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23